ReviewDie Anaesthesiologie2025
[Treatment of cancer-related pain-From pharmacotherapy to invasive procedures].
Review in Die Anaesthesiologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Depending on the stage of the tumor up to 80% of the patients suffer from cancer-related pain but treatment is often inadequate. Multiple causes can trigger pain and these can be due to the tumor itself, its secondary consequences but also treatment related. A differentiated assessment and individually tailored treatment of cancer-related pain not only improve the quality of life but also reduce the risk of pain chronification. A differentiation between nociceptive pain and pain caused by hypersensitivity is a mandatory requirement for adequate pharmacotherapy. There is a risk of inadequate pain control, particularly with a lack of consideration and treatment of hypersensitivity, e.g., with anticonvulsants or analgesic antidepressants. Opioids are an integral part of drug treatment for cancer-related pain and especially for the treatment of breakthrough cancer pain. The risk of abuse should be considered. Other substance groups are suitable for special pain situations or in cases refractory to treatment. Nonpharmacological treatment options should also be considered, in particular by offering low-threshold access to psychotherapeutic or psycho-oncological options. Invasive procedures can be a useful supplement. These range from patient-controlled subcutaneous or intravenous infusion pump systems and intrathecal drug administration up to neurolytic and ablative procedures. Due to the invasiveness of these procedures, an interdisciplinary approach is recommended to confirm the indications.
Indexed as
Identifiers
39668231What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.